UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 277

Sortiert nach

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Nature medicine, 2020-01, Vol.26 (1), p.47-51

2020

Link zum Volltext

Verfügbarkeit prüfen

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-10, Vol.34 (28), p.3383-3389

2016

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety

Therapeutic Advances in Respiratory Disease, 2018-01, Vol.12, p.1753466618801167-1753466618801167

Hida, Toyoaki

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

Clinical cancer research, 2019-09, Vol.25 (18), p.5485-5492

2019

Link zum Volltext

Verfügbarkeit prüfen

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer

Oncotarget, 2017-11, Vol.8 (61), p.103117-103128

2017

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis by Volatile Organic Compounds in Exhaled Breath from Lung Cancer Patients Using Support Vector Machine Algorithm

Sensors (Basel, Switzerland), 2017-02, Vol.17 (2), p.287-287

2017

Link zum Volltext

Verfügbarkeit prüfen

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.195-199

2020

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

Clinical cancer research, 2006-10, Vol.12 (19), p.5764-5769

2006

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial

Cancer science, 2018-06, Vol.109 (6), p.1930-1938

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Cancer science, 2018-09, Vol.109 (9), p.2863-2872

2018

Link zum Volltext

Verfügbarkeit prüfen

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

Cancer science, 2021-04, Vol.112 (4), p.1556-1566

2021

Link zum Volltext

Verfügbarkeit prüfen

Development of an Exhaled Breath Monitoring System with Semiconductive Gas Sensors, a Gas Condenser Unit, and Gas Chromatograph Columns

Sensors (Basel, Switzerland), 2016-11, Vol.16 (11), p.1891

2016

Link zum Volltext

Verfügbarkeit prüfen

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP

Journal of clinical oncology, 2017-05, Vol.35 (14), p.1515-1521

2017

Link zum Volltext

Verfügbarkeit prüfen

Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill

Anti-cancer drugs, 2016-07, Vol.27 (6), p.573-575

2016

Link zum Volltext

Verfügbarkeit prüfen

Inflammation Flare and Radiation Necrosis Around a Stereotactic Radiotherapy-Pretreated Brain Metastasis Site After Nivolumab Treatment

Journal of thoracic oncology, 2018-12, Vol.13 (12), p.1975-1978

2018

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis

Cancer science, 2019-09, Vol.110 (9), p.2884-2893

2019

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer

Clinical cancer research, 2008-10, Vol.14 (19), p.6092-6096

2008

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer

Cancer science, 2017-05, Vol.108 (5), p.1000-1006

2017

Link zum Volltext

Verfügbarkeit prüfen

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

Clinical cancer research, 2009-07, Vol.15 (13), p.4493-4498

2009

Link zum Volltext

Verfügbarkeit prüfen

EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma

Journal of thoracic oncology, 2015-12, Vol.10 (12), p.1720-1725

2015

Link zum Volltext

Verfügbarkeit prüfen

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study

Cancer science, 2020-10, Vol.111 (10), p.3726-3738

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 277

Suche als RSS-Feed

Aktive Filter

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(211)
Mit Volltextzugriff
(268)

Publikationsform

Artikel
(270)
Berichte
(7)

Sprache

Englisch
(240)
Japanisch
(61)

Erscheinungsjahr

n.n

Thema

Science & Technology
(139)
Life Sciences & Biomedicine
(137)
Oncology
(119)
Humans
(106)
Female
(72)
Male
(72)
Middle Aged
(69)
Aged
(67)
Lung Cancer
(63)
Lung Neoplasms - Drug Therapy
(63)
Adult
(56)
Lung Neoplasms - Pathology
(53)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(52)
Lung Neoplasms - Genetics
(51)
Respiratory System
(45)
Carcinoma, Non-Small-Cell Lung - Genetics
(36)
Aged, 80 And Over
(35)
Mutation
(34)
Non-Small Cell Lung Cancer
(29)
Treatment Outcome
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(38)
Journal Of Thoracic Oncology
(26)
Japanese Journal Of Lung Cancer
(17)
Lung Cancer
(17)
Japanese Journal Of Clinical Oncology
(12)
Cancer Research
(11)
Cancer Science
(10)
Haigan. Lung Cancer
(10)
Annals Of Oncology
(8)
Clinical Cancer Research
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer

Diagnosis by Volatile Organic Compounds in Exhaled Breath from Lung Cancer Patients Using Support Vector Machine Algorithm

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

Development of an Exhaled Breath Monitoring System with Semiconductive Gas Sensors, a Gas Condenser Unit, and Gas Chromatograph Columns

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP

Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill

Inflammation Flare and Radiation Necrosis Around a Stereotactic Radiotherapy-Pretreated Brain Metastasis Site After Nivolumab Treatment

Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer

Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations

EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study

Aktive Filter

Suchergebnisse filtern